{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:14:22Z","timestamp":1788513262780,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,4]]},"DOI":"10.7759\/cureus.115758","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:26:21Z","timestamp":1788510381000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Indrajit","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mooroogiah","family":"Krissheeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00511-3","article-title":"Polycystic ovary syndrome","volume":"10","author":"Stener-Victorin E","year":"2024","unstructured":"Stener-Victorin E, Teede H, Norman RJ, et al.. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024, 10:27. 10.1038\/s41572-024-00511-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede HJ","year":"2026","unstructured":"Teede HJ, Khomami MB, Morman R, et al.. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026, 407:2329-39. 10.1016\/S0140-6736(26)00717-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome","volume":"108","author":"Teede HJ","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJ, et al.. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023, 108:2447-69. 10.1210\/clinem\/dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvag033","article-title":"GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis","volume":"194","author":"Forslund M","year":"2026","unstructured":"Forslund M, W\u00e4ndell P, Forsberg L, et al.. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis. Eur J Endocrinol. 2026, 194:25-39. 10.1093\/ejendo\/lvag033","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16422","article-title":"Metformin use in women with polycystic ovary syndrome (PCOS): opportunities, benefits, and clinical challenges","volume":"27 Suppl 3","author":"Saadati S","year":"2025","unstructured":"Saadati S, Mason T, Godini R, Vanky E, Teede H, Mousa A. Metformin use in women with polycystic ovary syndrome (PCOS): opportunities, benefits, and clinical challenges. Diabetes Obes Metab. 2025, 27 Suppl 3:31-47. 10.1111\/dom.16422","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/17455057241311759","article-title":"Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: effects on pathophysiologic process and fertility outcomes","volume":"21","author":"Brand KM","year":"2025","unstructured":"Brand KM, Gottwald-Hostalek U, Andag-Silva A. Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: effects on pathophysiologic process and fertility outcomes. Womens Health (Lond). 2025, 21:17455057241311759. 10.1177\/17455057241311759","journal-title":"Womens Health (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han Y","year":"2019","unstructured":"Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019, 39:332-42. 10.1016\/j.rbmo.2019.04.017","journal-title":"Reprod Biomed Online"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou L","year":"2023","unstructured":"Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023, 23:245. 10.1186\/s12902-023-01500-5","journal-title":"BMC Endocr Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg A","year":"2024","unstructured":"Goldberg A, Graca S, Liu J, et al.. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024, 25:e13704. 10.1111\/obr.13704","journal-title":"Obes Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.103927","article-title":"Effects of GLP-1 receptor agonists vs metformin in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Almubaddil K","year":"2026","unstructured":"Almubaddil K, Alotaibi M, Bin Mutreb L, Alanazi F, Altulihee M. Effects of GLP-1 receptor agonists vs metformin in polycystic ovary syndrome: a systematic review and meta-analysis. Cureus. 2026, 18:e103927. 10.7759\/cureus.103927","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref12","unstructured":"Comparative efficacy, safety, menstrual cycle regulation and weight outcomes of liraglutide versus metformin in women with polyendocrine metabolic ovarian syndrome (PMOS). a systematic review and meta-analysis. (2026). Accessed: 29 July, 2026: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261435182."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21:1539-58. 10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"ref16","unstructured":"Review Manager (RevMan Web). (2024). Accessed. July 10, 2026: http:\/\/revman.cochrane.org."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome","volume":"14","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015, 14:81-90. 10.1007\/BF03401383","journal-title":"Hormones (Athens)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015, 8:32. 10.1186\/s13048-015-0161-3","journal-title":"J Ovarian Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-119041","article-title":"Effects of metformin on endocrine and metabolic parameters in patients with polycystic ovary syndrome","volume":"49","author":"Zahra M","year":"2017","unstructured":"Zahra M, Shah M, Ali A, Rahim R. Effects of metformin on endocrine and metabolic parameters in patients with polycystic ovary syndrome. Horm Metab Res. 2017, 49:103-8. 10.1055\/s-0042-119041","journal-title":"Horm Metab Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0113","article-title":"Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential","volume":"6","author":"Nylander M","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017, 6:89-99. 10.1530\/EC-16-0113","journal-title":"Endocr Connect"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.04.013","article-title":"Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study","volume":"112","author":"Lingaiah S","year":"2019","unstructured":"Lingaiah S, Morin-Papunen L, Risteli J, Tapanainen JS. Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study. Fertil Steril. 2019, 112:362-70. 10.1016\/j.fertnstert.2019.04.013","journal-title":"Fertil Steril"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.06.015","article-title":"Effect of metformin on microvascular endothelial function in polycystic ovary syndrome","volume":"94","author":"Heidari B","year":"2019","unstructured":"Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc. 2019, 94:2455-66. 10.1016\/j.mayocp.2019.06.015","journal-title":"Mayo Clin Proc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch KE","year":"2022","unstructured":"Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022, 118:371-81. 10.1016\/j.fertnstert.2022.04.027","journal-title":"Fertil Steril"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.106751","article-title":"Effectiveness of GLP-1 receptor agonists in patients with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"18","author":"Buragohain S","year":"2026","unstructured":"Buragohain S, Sarma I, Saikia D, Malakar H, Das BK, Khound M, Lahon J. Effectiveness of GLP-1 receptor agonists in patients with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Cureus. 2026, 18:e106751. 10.7759\/cureus.106751","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99622-4","article-title":"Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials","volume":"15","author":"Lin S","year":"2025","unstructured":"Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025, 15:16512. 10.1038\/s41598-025-99622-4","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.25259\/GJMPBU_73_2026","article-title":"Efficacy and safety of letrozole versus clomiphene citrate in polyendocrine metabolic ovarian syndrome: a systematic review, meta-analysis, and grade assessment of randomized controlled trials","volume":"21","author":"Banerjee I","year":"2026","unstructured":"Banerjee I, Mooroogiah K, Banerjee I, Yagnik VD. Efficacy and safety of letrozole versus clomiphene citrate in polyendocrine metabolic ovarian syndrome: a systematic review, meta-analysis, and grade assessment of randomized controlled trials. Glob J Med Pharm Biomed Update. 2026, 21:22. 10.25259\/GJMPBU_73_2026","journal-title":"Glob J Med Pharm Biomed Update"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/519471-comparative-efficacy-and-safety-of-liraglutide-versus-metformin-in-women-with-polyendocrine-metabolic-ovarian-syndrome-pmos-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:26:22Z","timestamp":1788510382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/519471-comparative-efficacy-and-safety-of-liraglutide-versus-metformin-in-women-with-polyendocrine-metabolic-ovarian-syndrome-pmos-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.115758","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}